克拉丁-克拉迪宾和多发性硬化症的先天免疫反应 - 一项第四期前性研究
Mastura Monif1, Richard P Sequeira2, Andrea Muscat2
1Department of Neuroscience, Monash University, Melbourne, VIC, Australia; Department of Neurology, Melbourne Health, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia; Department of Physiology, The University of Melbourne, Melbourne, VIC, Australia.
Clinical immunology (Orlando, Fla.)
|July 4, 2024
概括
对复发性缓解性MS的克拉迪宾治疗显著减少了非经典单细胞和改变了P2X7受体活性. 这揭示了克拉迪宾的新型作用机制,表明其在其他神经炎症疾病中的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉迪宾 (Mavenclad®) 是治疗复发性缓解性多发性硬化症 (RRMS) 的口服疗法.
- 确切的作用机制和对先天免疫力的影响尚不清楚.
- 了解克拉德里宾对免疫细胞的影响对于优化其治疗用途至关重要.
研究的目的:
- 为了研究克拉迪宾对RRMS患者外围单细胞的作用机制.
- 在体外和体内评估克拉迪宾对P2X7受体 (P2X7R) 的影响.
- 探索克拉迪宾的新型治疗应用.
主要方法:
- 未来的第四阶段研究涉及41名RRMS患者.
- 在施用克拉迪后对外围单细胞子集 (CD14,CD16) 的分析.
- 测量血清细胞因子 (例如,CCL2).
- 在体外评估P2X7R毛孔和通道活性.
主要成果:
- 在治疗后的第一周,整体单细胞数显著减少.
- 最受影响的单细胞子组:CD14lo CD16+"非经典"单细胞.
- 第1周血清CCL2水平升高.
- 在体外:克拉迪宾降低了P2X7R毛孔和通道活性.
结论:
- 克拉迪宾通过向特定的单细胞子集和P2X7R活性来发挥一种新的作用机制.
- 这些发现支持进一步调查cladribine对渐进性MS形式的治疗.
- 克拉迪宾的潜在益处可能扩展到其他神经退行性疾病,包括先天性免疫炎症.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128